2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

01/18/2008
MGI PHARMA Announces Results from Study Involving the Dual Implantation of Gliadel(R) Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme

01/07/2008
Notice of Correction to Notice of Conversion Right for Senior Subordinated Convertible Notes Due 2024

01/03/2008
MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules Accepted for Review by U.S. FDA

12/26/2007
Notice of Conversion Right for Senior Subordinated Convertible Notes Due 2024

12/17/2007
MGI PHARMA Announces Aquavan NDA Accepted for Review by U.S. FDA

12/10/2007
Dacogen(R) (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition

12/10/2007
Eisai To Acquire MGI Pharma For $41 Per Share In An All Cash Transaction

11/29/2007
MGI PHARMA Issues Statement

11/27/2007
MGI PHARMA To Present at The BMO Capital Markets 7th Annual Focus on Healthcare Conference

11/20/2007
MGI PHARMA To Present at the Lazard Capital Markets 4th Annual Healthcare Conference

10/29/2007
MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug Application for Aloxi(R) Capsules

10/22/2007
Aquavan(R) Phase 3 Bronchoscopy Data Presented At CHEST 2007

10/17/2007
MGI PHARMA Reports Third Quarter 2007 Financial Results

10/15/2007
Aloxi(R) Phase 3 Data for Post Operative Nausea and Vomiting (PONV) Presented at the Annual Meeting of the American Society of Anesthesiologists (ASA)

10/11/2007
AkaRx and MGI PHARMA Announce Closing of Development and License Agreement

10/10/2007
MGI PHARMA Third Quarter 2007 Financial Results Conference Call to Be Webcast on October 17, 2007

09/27/2007
MGI PHARMA Announces Submission of Aquavan(R) New Drug Application

09/19/2007
MGI PHARMA Announces Change to Presentation Time at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Devices Conference

09/18/2007
MGI PHARMA to Present at the UBS Global Life Sciences Conference

09/12/2007
MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical Biotechnology and Medical Devices Conference

09/04/2007
MGI PHARMA and HELSINN Announce Aloxi(R) sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens

09/04/2007
MGI PHARMA to Present at the Bear Stearns 20th Annual Healthcare Conference

08/28/2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia

07/18/2007
MGI PHARMA Reports Second Quarter 2007 Financial Results

07/11/2007
MGI PHARMA Second Quarter 2007 Financial Results Conference Call to Be Webcast on July 18, 2007

07/11/2007
MGI PHARMA to Expand Presence in Lexington, MA

07/09/2007
MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA

06/04/2007
MGI PHARMA Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

05/24/2007
MGI PHARMA to Present at the Bank of America Healthcare Conference

05/23/2007
Aquavan(R) (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

05/07/2007
MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug Application for Aloxi(R) Injection in Post-Operative Nausea and Vomiting

04/18/2007
MGI PHARMA Reports First Quarter 2007 Financial Results

04/11/2007
MGI PHARMA First Quarter 2007 Financial Results Conference Call to Be Webcast on April 18, 2007

03/20/2007
MGI PHARMA Announces Positive Results from a Pivotal Phase 3 Study of Aquavan(R) Injection in Patients Undergoing Bronchoscopy

03/14/2007
MGI PHARMA Announces Change to Presentation Date and Time at the Lehman Brothers 10th Annual Global Healthcare Conference

03/14/2007
MGI PHARMA to Present at the Lehman Brothers 10th Annual Global Healthcare Conference

03/08/2007
MGI PHARMA to Present at the Cowen and Company 27th Annual Healthcare Conference

03/01/2007
MGI PHARMA Amends Quarterly Filings for Second and Third Quarters of 2006

02/13/2007
MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent Extension for Aloxi® Injection

02/07/2007
MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results

01/31/2007
MGI PHARMA to Present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

01/31/2007
MGI PHARMA Fourth Quarter and Year End 2006 Financial Results Conference Call to Be Webcast on February 7, 2007

01/17/2007
MGI PHARMA Announces Publication of Phase 3 Data for Saforis(TM) (glutamine) Powder in UpTec(TM) for Oral Suspension in Cancer

01/03/2007
MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare Conference

01/03/2007
MGI PHARMA Announces Publication of Phase 2 Data Describing Dacogen(TM) (Decitabine) for Injection in Blood

12/14/2006
MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi(R) (Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting

12/11/2006
Dacogen(TM) (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition

11/20/2006
MGI PHARMA to Present at the Lazard Capital Markets Third Annual Life Sciences Conference

11/20/2006
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting

11/02/2006
MGI PHARMA Recognized for Innovation & Growth

10/31/2006
MGI PHARMA Announces Specific J Code Assignment for Dacogen(TM)

10/18/2006
MGI PHARMA Reports Third Quarter 2006 Financial Results

10/12/2006
MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension

10/11/2006
MGI PHARMA Third Quarter 2006 Financial Results Conference Call to Be Webcast on October 18, 2006

09/19/2006
MGI PHARMA to Present at the UBS Global Life Sciences Conference

09/05/2006
MGI PHARMA To Present at the Bear Stearns 19th Annual Healthcare Conference

08/10/2006
Dacogen(TM) (Decitabine) for Injection Receives U.S. Orphan Drug Designation for Patients with AML

08/07/2006
MGI PHARMA Announces Executive Appointments

08/03/2006
MGI PHARMA To Present at the Bank of America Specialty Pharmaceuticals Conference

08/01/2006
Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML

07/26/2006
Dr. James Armitage Appointed to MGI PHARMA Board of Directors

07/19/2006
MGI PHARMA Reports Second Quarter 2006 Financial Results

07/19/2006
MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25, 2006

07/12/2006
MGI PHARMA Second Quarter 2006 Financial Results Conference Call to Be Webcast on July 19, 2006

07/06/2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection; Ex-North America Development & Commercialization Agreement

06/12/2006
Saforis(TM) NDA Accepted by U.S. FDA for Priority Review; PDUFA Date of October 12, 2006 Established

06/05/2006
MGI PHARMA Summarizes Clinical Data Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2006
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection

05/25/2006
Dr. Gerard T. Kennealey Joins MGI PHARMA as Senior Vice President, Clinical Development

05/11/2006
MGI PHARMA to Present at the 2006 Bank of America Health Care Conference

05/04/2006
MGI PHARMA To Present at the Baird 2006 Growth Stock Conference

05/03/2006
U.S. FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM) Approved for Patients with all FAB Classifications of MDS; Commercial Launch Planned For Late May

04/24/2006
MGI PHARMA Appoints William F. Spengler As CFO

04/19/2006
MGI PHARMA Reports First Quarter 2006 Financial Results; First Quarter Highlighted by Execution of Pipeline Initiatives

04/18/2006
MGI PHARMA Announces Publication of Phase 3 Data for Dacogen(TM) (Decitabine) for Injection in Cancer

04/17/2006
MGI PHARMA To Present at the 2006 UBS Global Specialty Pharmaceuticals Conference

04/13/2006
MGI PHARMA First Quarter 2006 Financial Results Conference Call to Be Webcast on April 19, 2006

04/13/2006
MGI PHARMA Announces Submission of Saforis(TM) NDA to U.S. FDA

04/13/2006
MGI PHARMA Updates Outlook for First Quarter

03/20/2006
MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal Program; Patient Enrollment Expected To Conclude By Year-End

03/08/2006
Gliadel(R) Wafer Demonstrates Long-Term Survival Benefit for Patients with High-Grade Malignant Gliomas

03/03/2006
MGI PHARMA To Present at the Lehman Brothers 9th Annual Global Healthcare Conference

02/09/2006
CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and Full Year 2005 Financial Results

02/08/2006
MGI PHARMA Reports Fourth Quarter and Full Year 2005 Financial Results

02/07/2006
MGI PHARMA to Present at the BIO CEO and Investor Conference

02/02/2006
MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Devices Conference

02/01/2006
MGI PHARMA Fourth Quarter and Year End 2005 Financial Results Conference Call to Be Webcast on February 8, 2006

01/10/2006
MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection Sales Increase 56% To Approximately $248 Million; 2006 Sales of Aloxi(R) Injection Expected To Range From $285-$300 Million

12/21/2005
MGI PHARMA to Present at the JPMorgan Healthcare Conference

12/21/2005
MGI PHARMA Provides Update on Aquavan(R) Injection Program; Top Line Results of Successful Phase 2 Dose Ranging Study Summarized; Aquavan(R) Injection Pivotal Program Planned to Begin in Early 2006

12/15/2005
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for Review By U.S. FDA

12/12/2005
Dacogen(TM) (Decitabine) Injection Data Presented at American Society of Hematology (ASH) Annual Meeting; Updated Data From Alternative Dosing Regimen Study And Initial Phase 2 AML Results Presented

12/01/2005
MGI PHARMA to Present at the NASDAQ 16th Investor Program

11/29/2005
MGI PHARMA Announces Expiration of Tender Offer for Guilford Pharmaceuticals Notes Due 2008

11/22/2005
MGI PHARMA to Present at the Lazard Capital Markets Life Sciences Conference

11/15/2005
MGI PHARMA And SuperGen Provide Regulatory Status Updates For Dacogen(TM) (Decitabine) Injection For MDS; Approvable Letter Response Submitted to FDA; Confirms Phase 3 Results; European Regulatory Strategy Revised

10/26/2005
MGI PHARMA and SuperGen Provide Regulatory Updates for Dacogen(TM) (Decitabine) Injection for MDS

10/20/2005
MGI PHARMA Announces Commencement of Tender Offer for Guilford Pharmaceutical Notes Due 2008

10/19/2005
MGI PHARMA Reports Third Quarter Financial Results

10/19/2005
MGI PHARMA Ranked Among Top Half of Fastest Growing North American Technology Companies on 2005 Deloitte Technology Fast 500; Company Posts 676% Revenue Growth from 2000-2004